USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Global Antibody Drug Conjugate (ADC) Growth Opportunities, Forecast to 2028
Global Antibody Drug Conjugate (ADC) Growth Opportunities, Forecast to 2028
Collaborations with Innovative Platform Developers will Drive Growth Potential
17-Jul-2023
Global
Market Research
Description
This research service overviews the global ADC market and provides a 6-year revenue forecast from 2023 to 2028. An ADC comprises multiple components such as the antibody, conjugation chemistry, linker, and payload. Many companies are working on each component while others only develop ADCs, which makes the market highly competitive. The development of targeted delivery vehicles over standard antibodies is improving the performance of these drugs and expanding their potential for treating new cancers. New technologies are trying to address drawbacks of existing ADC technology, such as poor stability, leading to poor tolerability, efficacy, and a narrow therapeutic index and challenging ADC manufacturing.
Frost & Sullivan’s analysis shows that small and mid-sized enterprises that rely on contract development and manufacturing organizations (CDMOs)/contract research organizations (CROs) for initial drug development create novel antibody therapeutic technologies. Many antibody developers have been decreasing in-house R&D efforts and increasing in-licensing or acquiring therapeutic antibody product lines to strengthen their pipelines. All major CDMOs are stepping up with new investments to support the next generation of ADC, making the segment more competitive. Biopharmaceutical companies are focusing on ADCs to reap the benefits of target specificity for selective tumor antigens. Developers are using robust approaches to improve payloads’ potency as ADCs reflect the success rate in the last two years with seven approvals.
Other information included in the report consists of the following:
• Market trends
• Leading disruptors
• Marketed and pipeline ADC that will drive growth in hematological and solid tumors
• Growth opportunities emerging from this space that stakeholders can leverage
Author: Surbhi Gupta
Table of Contents
Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the ADC Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Scope of Analysis
ADC Market Highlights
Growth Opportunities: The ADC Market
Growth Drivers
Growth Restraints
Drug Conjugates’ History, Progress, and Research Stages
ADC Market Trends
ADC Technology Evolution
Precision Oncology Approaches for ADCs
Biomarker Application Across the Cancer Continuum
Life Cycle Management Strategies
ADC Deals and Investment Outlook
Notable ADC Partnerships and Collaborations, 2022
Notable ADC Partnerships and Collaborations, 2022 (continued)
Notable ADC Partnerships and Collaborations, 2022 and 2023
Approved ADCs: Hematological Cancer
Approved ADCs: Solid Tumors
Late-stage ADCs to Watch
Forecast Assumptions
Growth Metrics
Revenue Forecast
Revenue Forecast Analysis: Solid Tumors (Launched)
Revenue Forecast Analysis: Solid Tumors (Launched) (continued)
Revenue Forecast Analysis: Solid Tumors (Launched) (continued)
Revenue Forecast Analysis: Solid Tumors (Pipeline)
Revenue Forecast Analysis: Hematological Cancer (Launched)
Revenue Forecast Analysis: Hematological Cancer (Launched) (continued)
Revenue Forecast Analysis: Hematological Cancer (Late-stage Pipeline)
Tubulis: Broad Spectrum of Technology Platforms
LCB: Conjugation Technology Platforms
Synaffix (Lonza): End-to-end ADC Services
WuXi Biologics: ADC CRDMO
Mersana Therapeutics: Late-stage ADC Pipeline and Platform
Iksuda: A Toolbox Approach for ADC Development
Growth Opportunity 1: ADC Combination Therapies for Precision Chemotherapeutics
Growth Opportunity 1: ADC Combination Therapies for Precision Chemotherapeutics (continued)
Growth Opportunity 2: Strategic Partnerships between CDMOs and Early-stage Platform and ADC Developers
Growth Opportunity 2: Strategic Partnerships between CDMOs and Early-stage Platform and ADC Developers (continued)
Growth Opportunity 3: Novel Linkers and Conjugation Chemistries
Growth Opportunity 3: Novel Linkers and Conjugation Chemistries (continued)
List of Exhibits
Legal Disclaimer
Popular Topics
| Deliverable Type | Market Research |
|---|---|
| Author | Surbhi Gupta |
| Industries | Healthcare |
| No Index | No |
| Is Prebook | No |
| Keyword 1 | Antibody Drug Conjugate |
| Keyword 2 | Adc Drug |
| Keyword 3 | Drug Conjugate |
| Podcast | No |
| WIP Number | PED8-01-00-00-00 |